CLAIMS

1. Use of compound a) in the manufacture of a medicament for the prophylaxis or treatment of glioblastoma, wherein compound a) is to be administered in combination with compound b), and wherein the compounds a) and b) are:

a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;

b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.

2. Use of compound b) in the manufacture of a medicament for the prophylaxis or treatment of glioblastoma, wherein compound b) is to be administered in combination with compound a), and wherein the compounds a) and b) are:

a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;

b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.

3. Use of compounds a) and b) in the manufacture of a medicament for the prophylaxis or treatment of glioblastoma, wherein compounds a) and b) are to be administered in combination, and wherein the compounds a) and b) are:

a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;

b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.

4. The use according to any one of claims 1-3, wherein the inhibitor is bevacizumab.

5. The use according to any one of claims 1 to 4, wherein compounds a) and b) are to be administered simultaneously.

6. The use according to any one of claims 1 to 2 and 4, wherein compounds a) and b) are to be administered sequentially.